ACQUIRED · 2023
Who Acquired Axolotl Biologix?
Carmell Therapeutics Corporation · $65.0M· 13.0× EBITDA
The acquisition
Axolotl Biologix was acquired by Carmell Therapeutics Corporation in 2023 for $65.0M. The deal was priced at 13.0× EBITDA / 1.30× revenue.
Axolotl Biologix at time of acquisition
Revenue
$50.0M
EBITDA
$5.0M
Deal value
$65.0M
EV / EBITDA
13.0×
Similar medical devices acquisitions
- Owen Mumford Holdings · acquired by Embecta in 2026 · $201.0M
- Acera Surgical · acquired by Solventum in 2025 · $725.0M
- Alydia Health (Organon JADA System) · acquired by Laborie Medical Technologies in 2025 · $440.0M
- B Medical Systems (Azenta) · acquired by THELEMA S.A. R.L. in 2025 · $63.0M
- BIOTRONIK Vascular Intervention Business · acquired by Teleflex, Inc. in 2025 · $875.9M
Run a valuation for a similar medical devices business
Three fields, instant range, backed by 25,592 real M&A transactions including this one.
Open the medical devices calculator →More on medical devices valuations
- Medical Devices valuation calculator· head-term variant
- Medical Devices median multiples· real-deal benchmarks
- How to value a medical devices· long-form guide
Sourced from Press release. Full deal page.
Citation: ExitValue.ai. (2023). Axolotl Biologix acquired by Carmell Therapeutics Corporation. https://exitvalue.ai/acquired/axolotl-biologix